DNA Synthesis Market Size & Share 2026-2035

DNA Synthesis Market Size

The global DNA synthesis market was valued at USD 2.5 billion in 2025. The market is expected to grow from USD 2.9 billion in 2026 to USD 11.5 billion in 2035, at a CAGR of 16.3% during the forecast period, according to the latest report published by Global Market Insights Inc.

The growth of the market is primarily driven by the increasing demand for synthetic DNA across molecular biology, genetic engineering, synthetic biology, and clinical diagnostics applications. Rising prevalence of chronic and genetic diseases, coupled with growing research activities in drug discovery, vaccine development, and personalized medicine, is significantly supporting market expansion. In addition, continuous technological advancements in genomics and DNA synthesis platforms, increasing investments in biotechnology research, and the availability of advanced synthesis services are expected to further accelerate market growth during the forecast period.

DNA synthesis refers to the artificial creation of DNA sequences through chemical or enzymatic methods in a laboratory environment. The technology enables the precise design and production of customized genetic material for various applications, including gene editing, therapeutic development, molecular diagnostics, vaccine production, and synthetic biology research. DNA synthesis plays a critical role in enabling innovations in biotechnology by facilitating the development of engineered genes, pathways, and biological systems for both research and commercial applications.

Major companies operating in the market include Thermo Fisher Scientific, Integrated DNA Technologies, GenScript, Twist Bioscience, Eurofins Scientific, Bioneer Corporation, Synbio Technologies, OriGene Technologies, and Agilent Technologies. These companies are focusing on improving synthesis accuracy, scalability, and turnaround times while expanding their gene and oligonucleotide synthesis capabilities. Strategic investments in automation technologies, enzymatic DNA synthesis, AI-enabled sequence optimization, and manufacturing capacity expansion, along with mergers, acquisitions, and partnerships, are further strengthening their market presence and service portfolios globally.

Between 2022 and 2024, the market witnessed strong and consistent growth driven by increasing adoption in molecular biology research, synthetic biology, and gene-based therapeutic development. During this period, the market expanded from approximately USD 1.3 billion in 2022 to nearly USD 2.1 billion in 2024. Growth was further supported by rising demand for custom DNA constructs, expanding use of CRISPR and advanced gene-editing technologies, increasing investments in biotechnology and pharmaceutical R&D, and broader utilization of DNA synthesis services by academic institutions, pharmaceutical companies, and contract research organizations across developed and emerging markets.
 

DNA Synthesis Market Trends

• Investments in DNA synthesis technologies have increased significantly as advancements in synthetic biology, genomics, and genetic engineering continue to expand application areas.
• Rising funding for research and development aimed at introducing innovative DNA synthesis technologies is expected to support market growth. For instance, Molecular Assemblies secured USD 25.8 million in funding from Casdin Capital to advance enzymatic DNA synthesis technology. Similarly, Twist Bioscience announced a USD 100 million private placement investment from investors including Casdin Capital, Fidelity Management & Research Company, and Viking Global Investors to strengthen its DNA synthesis platform. Such increasing investments are expected to accelerate technological innovation and drive overall market growth.
• A key market trend is the transition from traditional chemical synthesis methods toward advanced high-precision DNA synthesis platforms, with growing adoption of long-sequence gene synthesis, high-fidelity oligonucleotides, and customized constructs for applications in research, diagnostics, and therapeutics.
• The increasing adoption of personalized and precision medicine approaches is further expanding the role of DNA synthesis in customized gene design for CRISPR technologies, cell and gene therapies, vaccines development, and biomarker-based research, enabling more targeted clinical and research outcomes.
• The emergence of next-generation technologies such as enzymatic and cell-free DNA synthesis is reshaping the market by offering faster turnaround times, improved synthesis accuracy, greater scalability, and reduced dependence on conventional phosphoramidite chemistry.
• Expanding applications beyond traditional life sciences are also contributing to market growth, with synthetic DNA increasingly being utilized in DNA data storage, bio-computing, and advanced material development, thereby broadening commercial opportunities for DNA synthesis providers.
• Increasing integration of automation technologies, AI-enabled sequence design platforms, and biofoundry systems is transforming DNA synthesis workflows from manual and batch-based operations into highly automated, predictive, and high-throughput production environments.
• Additionally, growing emphasis on biosecurity, quality assurance, sequence screening, and regulatory compliance is driving investments in secure and traceable DNA synthesis platforms, strengthening customer confidence and industry standardization.

DNA Synthesis Market Analysis

Based on the service, the global DNA synthesis industry is segmented into oligonucleotide synthesis and gene synthesis. The oligonucleotide synthesis segment is further bifurcated into standard oligonucleotide synthesis and custom oligonucleotide synthesis. The oligonucleotide synthesis segment has asserted its dominance in the market by securing a significant market share and is anticipated to grow at a CAGR of 16% over the forecast years.

• The dominance of the oligonucleotide synthesis segment is primarily attributed to its extensive application in PCR, qPCR, sequencing, cloning, and gene-editing workflows. These short DNA sequences are essential consumables in both research and clinical laboratories, resulting in continuous and recurring demand.
• Strategic collaborations and product development initiatives by market participants are further supporting segment growth. For instance, in October 2022, Bachem entered into a collaboration with Eli Lilly and Company for the development and manufacturing of oligonucleotide-based active pharmaceutical ingredients (APIs).
• Furthermore, increasing adoption of molecular diagnostics, infectious disease testing, and genomics-based research is significantly driving demand for high-quality primers, probes, and custom oligonucleotides across pharmaceutical, biotechnology, and academic sectors.
• In contrast, the gene synthesis segment is projected to witness the fastest growth during the forecast period, registering a CAGR of 16.7%. This growth is driven by rising demand for complex and long DNA constructs used in synthetic biology, cell and gene therapy development, biologics research, and vaccine design.

By method, the DNA synthesis market is classified into solid phase synthesis, PCR-based enzyme synthesis and chip-based synthesis. The solid phase synthesis segment accounted for USD 918.8 million in 2025 and is projected to witness robust growth over the analysis timeframe.

• Solid-phase DNA synthesis enables precise and flexible synthesis of customized DNA sequences with specific lengths, modifications, and labeling capabilities, making it highly suitable for a wide range of biotechnology and research applications.
• The method offers high efficiency, scalability, and shorter turnaround times, enabling manufacturers to produce large volumes of synthetic DNA with consistent quality. These advantages are expected to continue supporting segment growth.
• Established manufacturing infrastructure and standardized synthesis chemistry protocols provide suppliers with strong cost-efficiency and high production output advantages compared to emerging synthesis technologies.
• Ongoing improvements in synthesis reagents, coupling efficiency, and purification technologies are further enhancing product quality and reliability, strengthening adoption among pharmaceutical companies, biotechnology firms, and research institutions.

Based on application, the DNA synthesis market is bifurcated into research & development, diagnostics and therapeutics. The research and development segment held the dominant position and is expected to reach over USD 4.8 billion in 2035.

• DNA synthesis serves as a fundamental technology in biotechnology and life sciences research, supporting applications such as drug discovery, genetic engineering, molecular biology, and development of diagnostic tests for infectious diseases, cancer, and genetic disorders.
• The growing use of DNA synthesis in synthetic biology and genomics research has significantly increased demand for custom oligonucleotides and gene constructs used in experimental workflows and model development.
• Increasing government and private investments in molecular biology, microbiology, and translational research programs globally are further strengthening the revenue contribution of the research & development segment.
• On the other hand, the therapeutics segment is expected to witness the fastest growth owing to the increasing development of cell and gene therapies, mRNA vaccines, and DNA-based therapeutics, all of which rely heavily on highly accurate synthetic DNA technologies.

Based on end use, the DNA synthesis market is bifurcated into academic and research institutes, contract research organizations and biopharmaceutical companies. The academic and research institutes segment held the dominant position by securing a significant market share of 54.5% in 2025.

• The dominance of academic and research institutes is supported by the extensive utilization of synthetic DNA in genomics, molecular cloning, functional biology, pathway engineering, and other fundamental research applications.
• Strong public and private funding support for life sciences research across universities, government laboratories, and research institutions continues to generate consistent demand for oligonucleotide and gene synthesis services.
• Increasing focus on synthetic biology, gene-editing technologies, and translational medicine is further expanding the application scope of DNA synthesis in academic and research environments.
• In contrast, contract research organizations (CROs) are anticipated to witness the fastest growth during the forecast period, driven by rising outsourcing of DNA synthesis, genomics, and molecular biology services by biotechnology and biopharmaceutical companies seeking cost optimization, scalability, and faster project turnaround times.

North America DNA Synthesis Market

The North America market dominated the global market with a market share of 38.7% in 2025.

• The region’s leadership is primarily attributed to increasing investments in biotechnology and genomics research, along with the strong presence of leading DNA synthesis companies and advanced research institutions. Government initiatives and strategic collaborations between industry participants are further supporting market growth.
• North America benefits from a highly developed biotechnology ecosystem comprising pharmaceutical companies, synthetic biology firms, contract research organizations, and academic institutions that extensively utilize high-throughput DNA synthesis technologies in drug discovery and research workflows.
• Strong venture capital funding and public investments in synthetic biology, precision medicine, genomics, and cell & gene therapy research are accelerating demand for custom oligonucleotides and gene synthesis services across the region.
• Increasing adoption of AI-enabled sequence design tools, automation platforms, and advanced biofoundry systems is further enhancing the efficiency and scalability of DNA synthesis operations in North America.

The U.S. DNA synthesis market was valued at USD 474.9 million and USD 598.6 million in 2022 and 2023, respectively. The market size reached USD 885.5 million in 2025, growing from USD 743.3 million in 2024.

• The U.S. market is driven by extensive utilization of DNA synthesis technologies in pharmaceutical and biotechnology research, academic studies, molecular diagnostics, and contract research organization (CRO)-supported therapeutic development programs.
• The country has a strong presence of synthetic biology startups, biotechnology innovators, and large-scale biofoundries, which is accelerating demand for rapid-turnaround and high-volume gene synthesis services.
• The U.S. is also witnessing increasing adoption of long-sequence and enzymatic DNA synthesis technologies for clinical-grade, GMP-compliant, and precision medicine applications.
• Furthermore, substantial federal funding for genomics research, rising investments in mRNA therapeutics and gene-editing technologies, and the expansion of personalized medicine initiatives continue to strengthen market growth.

Europe DNA Synthesis Market

Europe market accounted for USD 657.1 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• The market growth is supported by a strong academic research base, expanding biotechnology clusters, and increasing funding initiatives for genomics, molecular biology, and synthetic biology research across European countries.
• Growing focus on precision medicine, vaccine development, molecular diagnostics, and biologics research is contributing to sustained demand for high-quality DNA synthesis services and custom gene constructs.
• Increasing collaborations between research institutions, biotechnology firms, and pharmaceutical companies are further accelerating innovation and commercialization activities within the regional market.
• Additionally, rising investments in automated synthesis technologies and bio-manufacturing capabilities are supporting the expansion of large-scale DNA synthesis operations across Europe.

Germany dominates the Europe market, with strong growth potential.

• The country’s leadership is supported by extensive public research funding, strong university-industry collaborations, and the presence of a rapidly expanding synthetic biology startup ecosystem.
• Germany’s pharmaceutical, industrial biotechnology, and life sciences sectors increasingly rely on gene synthesis technologies for vaccine development, biologics production, strain engineering, and genomics research.
• The growing adoption of automated DNA synthesis platforms, high-fidelity oligonucleotides, and advanced gene-editing technologies is further contributing to market growth in the country.
• Furthermore, increasing government support for biotechnology innovation and expanding participation in European genomics research programs are strengthening Germany’s market position.

Asia Pacific DNA Synthesis Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 16.8% during the analysis timeframe.

• Rapidly increasing investments in life sciences research infrastructure, biotechnology innovation, and pharmaceutical manufacturing capabilities are significantly driving market growth across the region.
• Expansion of genomics initiatives, population-scale sequencing programs, and synthetic biology research projects in countries such as China, India, and Japan is generating substantial long-term demand for DNA synthesis technologies.
• Growing adoption of precision medicine, increasing clinical research activities, and rising outsourcing of genomics and molecular biology services are further supporting regional market expansion.
• In addition, supportive government policies aimed at strengthening domestic biotechnology industries and enhancing healthcare innovation are accelerating the adoption of advanced DNA synthesis platforms.

China DNA synthesis market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• The market growth is driven by the rapid expansion of domestic biotechnology companies, increasing investment in genomics research, and large-scale national synthetic biology programs.
• Strong government support for biotechnology innovation and bio-manufacturing is accelerating the adoption of DNA synthesis technologies across healthcare, agricultural biotechnology, and industrial applications.
• The country is also witnessing increasing demand for cost-effective and high-volume gene synthesis services due to the rapid expansion of CRO activities and pharmaceutical outsourcing operations.
• Furthermore, rising focus on research self-sufficiency, precision medicine, and next-generation therapeutic development is expected to continue strengthening China’s market

Latin American DNA Synthesis Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• The market growth is supported by increasing academic research activities, rising biotechnology startup formation, and growing adoption of molecular biology and genomics technologies across research institutions.
• Strengthening pharmaceutical manufacturing capabilities and increasing investments in vaccine and biologics research are driving demand for oligonucleotide and gene synthesis services in the country.
• The growing presence of global DNA synthesis providers through partnerships, regional distribution networks, and service expansion initiatives is improving access to advanced synthesis technologies in Brazil.
• In addition, rising government focus on biotechnology innovation and healthcare modernization is expected to further support market development across the country.

Middle East and Africa DNA Synthesis Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2025.

• The market is expanding due to rising investments in biotechnology infrastructure, genomics research, and healthcare modernization initiatives under national economic diversification strategies such as Vision 2030.
• Growing interest in precision medicine, genomic sequencing, and biosecurity applications is increasing demand for high-quality and regulated DNA synthesis solutions across the country.
• The establishment of advanced research centers, biotechnology parks, and academic collaborations is further supporting the adoption of DNA synthesis technologies in Saudi Arabia.
• Moreover, increasing government initiatives to strengthen domestic biotechnology capabilities and attract international life sciences investments are expected to contribute to long-term market growth.

DNA Synthesis Market Share

The global market is characterized by a moderately concentrated yet highly competitive landscape, in which a limited number of leading companies account for a substantial share of global revenues. Thermo Fisher Scientific, Integrated DNA Technologies (IDT), GenScript Biotech, Twist Bioscience, and Eurofins Scientific collectively contribute approximately 48% of the global market, supported by their advanced synthesis platforms, broad product and service portfolios, and strong global customer reach. These companies command leadership across key segments such as oligonucleotide synthesis, gene synthesis, and custom DNA services, serving a wide range of end users including biotechnology firms, pharmaceutical companies, academic institutes, and contract research organizations.

Competitive differentiation in the market is increasingly driven by technological capability, scale, and turnaround efficiency. Leading players leverage proprietary synthesis chemistries, high‑throughput automation, and integrated design‑to‑delivery workflows to maintain strong positions in both research‑grade and clinical‑grade DNA synthesis. Their dominance is further reinforced by deep investments in quality control, sequence fidelity, biosecurity screening, and compliance with regulatory and ethical standards, which are critical factors for customers operating in regulated therapeutic and diagnostic environments.

Strategic expansion through capacity investments, partnerships, and targeted technology acquisitions continues to shape the competitive landscape. For example, major players are expanding manufacturing infrastructure to support increasing demand for long and complex DNA constructs, while also investing in next‑generation platforms such as enzymatic and chip‑based synthesis. At the same time, innovation pipelines are being strengthened to address emerging applications in synthetic biology, cell and gene therapies, mRNA vaccines, and DNA‑based data storage. Collectively, these strategies position leading companies to capitalize on rising R&D investments, expanding therapeutic pipelines, and the growing importance of synthetic DNA as a foundational tool across life‑science and industrial biotechnology markets.

DNA Synthesis Market Companies

Prominent players operating in the DNA synthesis industry are as mentioned below:

• BIOMATIK
• Bioneer
• Eton Bioscience
• Eurofins Scientific
• GenScript Biotech
• IBA Lifesciences
• Integrated DNA Technologies
• Kaneka Eurogentec
• LGC Biosearch Technologies
• OriGene Technologies
• ProMab Biotechnologies
• ProteoGenix
• Quintara Biosciences
• Shenzhen Shuxin Biotechnology
• Synbio Technologies
• Thermo Fisher Scientific
• Twist Bioscience

 

• Thermo Fisher Scientific

Thermo Fisher Scientific holds a leading position in the market, supported by its comprehensive GeneArt portfolio spanning oligonucleotide synthesis, gene synthesis, and custom DNA solutions. The company’s strong market presence is reinforced by its global manufacturing footprint, deep integration across genomics, cell and gene therapy, and life‑science research tools, and consistent revenue growth from life‑science services.

• Integrated DNA Technologies (IDT)

Integrated DNA Technologies maintains a strong competitive position in the market, driven by its industry‑leading expertise in high‑quality oligonucleotide synthesis and precision DNA solutions. The company is widely recognized for its high‑fidelity products used across research, diagnostics, and clinical applications, particularly in PCR, next‑generation sequencing, and gene‑editing workflows.

• GenScript Biotech

GenScript Biotech plays a pivotal role in the global DNA synthesis landscape, supported by its broad gene and oligonucleotide synthesis portfolio and strong presence across synthetic biology and biologics research. The company’s competitive strength lies in its cost‑efficient service model, scalable production capabilities, and extensive support for early‑stage research through to advanced therapeutic development.

DNA Synthesis Industry News

• In January 2026, Integrated DNA Technologies entered a strategic collaboration with Ansa Biotechnologies to enable synthesis of long, high‑complexity DNA constructs of up to 50 kb. The partnership expanded IDT’s portfolio to include clonal DNA and XL clonal DNA products designed to overcome limitations in length and sequence accuracy.
• In April 2026, GenScript Biotech partnered with Mimulus Corp to industrialize DNA‑based data storage infrastructure aimed at large‑scale, long‑term molecular data archiving. The multi‑year collaboration focused on scaling DNA synthesis, platform development, and sequencing‑related technologies to support non‑electronic data preservation.
• In May 2023, GenScript Biotech Corporation launched its GenTitan Gene Fragments Synthesis service to expedite gene synthesis at lower cost. This is expected to help the company widen its service offerings and cater to a larger customer base.
• In January 2023, Twist Bioscience and Astellas entered into a multitarget antibody discovery research collaboration. This strategic collaboration aimed to discover antibodies against multiple targets of interest and curative therapies for patients suffering from diseases that lack treatment options. This strategy is expected to help the company to enhance its service offerings.

The DNA synthesis market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

By Service

• Oligonucleotide synthesis
  • Standard oligonucleotide synthesis
  • Custom oligonucleotide synthesis
• Gene synthesis
  • Custom gene synthesis
  • Gene library synthesis

By Method

• Solid phase synthesis
• PCR-based enzyme synthesis 
• CHIP-based DNA synthesis

By Application

• Research and development
• Diagnostics
• Therapeutics

By End Use

• Academic and research institutes
• Contract research organizations
• Biopharmaceutical companies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE